P J Declerck
Overview
Explore the profile of P J Declerck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tersteeg C, Joly B, Gils A, Lijnen R, Deckmyn H, Declerck P, et al.
J Thromb Haemost
. 2017 Oct;
15(12):2432-2442.
PMID: 28981198
Summary: Background Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening pathology, caused by occlusive von Willebrand factor (VWF)-rich microthrombi that accumulate in the absence of ADAMTS-13. We previously demonstrated that...
2.
Zhou X, Weeks S, Ameloot P, Callewaert N, Strelkov S, Declerck P
J Thromb Haemost
. 2016 Jun;
14(8):1629-38.
PMID: 27279497
Unlabelled: Essentials Thrombin-activatable fibrinolysis inhibitor (TAFI) is a risk factor for cardiovascular disorders. TAFI inhibitory nanobodies represent a promising step in developing profibrinolytic therapeutics. We have solved three crystal structures...
3.
Zhou X, Declerck P
J Thromb Haemost
. 2015 Mar;
13(6):1084-9.
PMID: 25773535
Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen that can be activated to form activated TAFI (TAFIa) (Ala93-Val401) through removal of the N-terminal activation peptide (Phe1-Arg92). TAFIa is thermally unstable,...
4.
Raeven P, Drechsler S, Weixelbaumer K, Bastelica D, Peiretti F, Klotz A, et al.
J Thromb Haemost
. 2014 Mar;
12(6):958-69.
PMID: 24655755
Background: The role of plasminogen activator inhibitor type-1 (PAI-1) in abdominal sepsis remains elusive. Objectives: To study the influence of inhibition and over-expression of PAI-1 upon survival in cecal ligation...
5.
Hendrickx M, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck P
J Thromb Haemost
. 2013 Dec;
12(2):229-36.
PMID: 24354544
Background: Down-regulation of fibrinolysis due to cleavage of C-terminal lysine residues from partially degraded fibrin is mainly exerted by the carboxypeptidase activity of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). Recently, some...
6.
Semeraro F, Ammollo C, Gils A, Declerck P, Colucci M
J Thromb Haemost
. 2013 Oct;
11(12):2137-47.
PMID: 24134522
Background: Recently, anti-thrombin-activatable fibrinolysis inhibitor (TAFI) mAbs selectively inhibiting plasmin-mediated TAFI activation were shown to stimulate fibrinolysis in vitro and in vivo, suggesting, in contrast to other findings, that plasmin-mediated...
7.
Wyseure T, Gils A, Declerck P
J Thromb Haemost
. 2013 Sep;
11(11):2069-71.
PMID: 24034450
No abstract available.
8.
Vercauteren E, Mutch N, Declerck P, Gils A
J Thromb Haemost
. 2012 Nov;
11(1):190-2.
PMID: 23140098
No abstract available.
9.
Vercauteren E, Peeters M, Hoylaerts M, Lijnen H, Meijers J, Declerck P, et al.
J Thromb Haemost
. 2012 Oct;
10(12):2555-62.
PMID: 23083123
Background: Mice with single gene deficiency of thrombin-activatable fibrinolysis inhibitor (TAFI) or plasminogen activator inhibitor-1 (PAI-1) have an enhanced fibrinolytic capacity. Objectives: To unravel the function and relevance of both...
10.
Mishra N, Buelens K, Theyskens S, Compernolle G, Gils A, Declerck P
J Thromb Haemost
. 2012 Apr;
10(6):1091-9.
PMID: 22498006
Background And Objectives: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen that can be activated by proteolytic cleavage into the active enzyme TAFIa. Hydrolysis of the C-terminal lysines on fibrin by...